Eli Lilly's (LLY) Zepbound has received 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea for adults with obes🍨ity, the drugmaker announced late 🔯Friday.

The approval comes after 澳洲幸运5官方开奖结果体彩网:several trials earlier this year that showed the tirzepatide-based drug is five times more effective than a placebo at 澳洲幸运5官方开奖结果体彩网:reduc🏅ing breathing disruptions caused by obstructive sleep apnea (OSA) and in 50% of cases, completely preventing them.

Zepbound Was Five Times Better at Reducing♔ Breathing 🐽Disruptions

Lilly said its final trial evaluated sleep apnea and weight loss in those taking Zepbound, with some patients using a traditional "positive airway pressure" (PAP) mask ༒while sleeping and others using ✤no mask. Among those not using a sleep apnea mask, Zepbound was about five times more effective than a placebo at reducing the number of breathing disruptions per hour, the company said.

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity," said Patrik Jonsson, president of Lilly USA.

The trials found that adults on Zepbound alone lost an average of 45 pounds, or 18% of their body weight, w꧅hile those adults on Zepbound combined with PAP therapy lost an average of🎀 50 pounds or 20% of their body weight.

"Nearly half of clinical trial patients saw such improvements that they no longer had symptoms associated with OSA, marking a critical step forward in reducing the burden of this disease and its interconnected health challenges," Jonsson said.

Zepbound got FDA approval to treat obesity and weight loss in 澳洲幸运5官方开奖结果体彩网:November 2023, joining Eli Lilly's other tirzepatide-based drug, Mounjaro. The two drugs, along with Novo Nordisk's (NVO) 澳洲幸运5官方开奖结果体彩网:Ozempic and Wegovy, have captured the majority of a 澳洲幸运5官方开奖结果体彩网:surging weight-loss market that has grown substantially in recent years.

Eli Lilly shares were up 1.6% at midday Monday, having gained about 34% on the year. Shares of ResMed (RMD), a medical device company that makes much of its revenue through the sale of sleep apnea masks, were 4% lower on Monday and have 澳洲幸运5官方开奖结果体彩网:been negatively affected previously by the sleep apnea trials for Zepbound.